Evoke Pharma (NASDAQ:EVOK) Shares Gap Down to $1.33

Share on StockTwits

Evoke Pharma Inc (NASDAQ:EVOK)’s stock price gapped down before the market opened on Wednesday . The stock had previously closed at $1.22, but opened at $1.33. Evoke Pharma shares last traded at $1.32, with a volume of 4,437 shares traded.

A number of equities analysts recently weighed in on the stock. HC Wainwright restated a “hold” rating on shares of Evoke Pharma in a research report on Friday, August 9th. ValuEngine upgraded shares of Evoke Pharma from a “sell” rating to a “hold” rating in a research report on Thursday, August 1st. Finally, Zacks Investment Research lowered shares of Evoke Pharma from a “buy” rating to a “hold” rating in a research report on Wednesday, October 23rd.

The stock’s 50-day moving average is $0.91 and its two-hundred day moving average is $0.84. The stock has a market cap of $32.23 million, a P/E ratio of -2.67 and a beta of 1.53.

Evoke Pharma (NASDAQ:EVOK) last issued its earnings results on Thursday, November 7th. The specialty pharmaceutical company reported ($0.07) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.09) by $0.02. On average, equities analysts forecast that Evoke Pharma Inc will post -0.35 EPS for the current fiscal year.

An institutional investor recently bought a new position in Evoke Pharma stock. Citadel Advisors LLC purchased a new stake in shares of Evoke Pharma Inc (NASDAQ:EVOK) during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 59,047 shares of the specialty pharmaceutical company’s stock, valued at approximately $37,000. Citadel Advisors LLC owned approximately 0.25% of Evoke Pharma as of its most recent SEC filing. Institutional investors own 5.70% of the company’s stock.

Evoke Pharma Company Profile (NASDAQ:EVOK)

Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray, which is completed Phase III clinical trials for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women.

Read More: What is meant by holder of record?

Receive News & Ratings for Evoke Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Intesa Sanpaolo SpA  Given Average Recommendation of “Hold” by Analysts
Intesa Sanpaolo SpA Given Average Recommendation of “Hold” by Analysts
$14.18 Million in Sales Expected for Quanterix Corp  This Quarter
$14.18 Million in Sales Expected for Quanterix Corp This Quarter
Sandy Spring Bancorp Inc.  Sees Significant Increase in Short Interest
Sandy Spring Bancorp Inc. Sees Significant Increase in Short Interest
EtherInc Trading Down 16.8% This Week
EtherInc Trading Down 16.8% This Week
Wagerr  Hits Market Cap of $5.89 Million
Wagerr Hits Market Cap of $5.89 Million
Fatcoin  Tops 1-Day Volume of $1.34 Million
Fatcoin Tops 1-Day Volume of $1.34 Million


© 2006-2019 Ticker Report